Latest Erlotinib Stories
A team of Brazilian scientists has identified a promising new combination treatment that targets cervical cancer, according to a new report published in the journal Cancer.
Highlights BGB324's potential as a novel treatment for NSCLC in patients with acquired drug resistance BERGEN, Norway, January 9, 2014 /PRNewswire/ -- Highlights
University of Cincinnati (UC) Cancer Institute researchers have found that using therapies specifically targeting the molecular profile of non-small-cell lung cancer with the mutated cancer-causing protein KRas is the most effective treatment strategy for patients with the condition.
The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.
Significant advances have taken place in the management of patients with advanced and metastatic non–small-cell lung cancer (NSCLC) over the last 5 years.
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.